Received: 20 December 2018
Accepted: 16 January 2019
First Online: 28 January 2019
Ethics approval and consent to participate
: This study was institutional-review board exempt and performed with de-identified participant user files from the National Cancer Database.
: Individual data is not contained in this manuscript.
: RRW provides consulting and/or advising services for Aettis, Inc., AstraZeneca, Genus, ImmunoVir LLC, Merck Serono S.A., Nano Proteagen, Reflexion Pharmaceuticals, RiMO, and Shuttle Pharmaceuticals. RRW participated in guest speaking with sponsored industry travel for Boehringer Ingelheim Ltd. RRW also has equity and/or intellectual property rights with Boost Therapeutics, Inc., Oncosenescence, Reflexion Pharmaceuticals, and RiMO. For the remaining authors no conflicts of interest were declared.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.